Navigation Links
Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Date:2/26/2008

op dose of the marketed AII antagonist. Numerous similar studies with other agents that block the renin-angiotensin system support that this result is a strong indication that PS433540 can be expected to lower blood pressure in hypertensive patients. Additional data from the MAD study demonstrated that PS433540 produced statistically significant, dose dependent increases versus placebo in plasma-renin activity, as well as reductions in systolic and diastolic blood pressure in non-hypertensive healthy volunteers.

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically validated mechanisms of action in a single compound. There is considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

About Pharmacopeia

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
9. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 /PRNewswire-iReach/ -- Reproductive Medicine Associates of New ... ), a nationally and internationally-recognized leader in providing exceptional ... is pleased to announce a new collaboration with EMD ... to recognize the sacrifices made by veterans and their ... Program will allow qualifying veterans and the spouses of ...
(Date:7/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... chief financial officer of the company, effective July 22, ... president and chief financial officer of Elan Corporation, a ... was part of a senior team that helped build ... to Perrigo, a pharmaceutical manufacturer, in December 2013. ...
(Date:7/22/2014)... , July 22, 2014 WuXi PharmaTech (Cayman) Inc. ... medical device R&D outsourcing company with operations in ... , today announced that it will release financial results for ... Exchange closes on Wednesday, August 13, 2014 (which will be ... will be available on the investor relations section of the ...
Breaking Medicine Technology:Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3ConvaTec Names Nigel Clerkin Chief Financial Officer 2WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2
(Date:7/22/2014)... from Boston University School of Medicine (BUSM) and ... who received care through BMC,s Violence Intervention Advocacy ... emotional and social needs of violently injured youthswere ... experienced life changing behaviors through connections to caring, ... and hope. These findings are reported in the ...
(Date:7/22/2014)... from the Sloan-Kettering Institute for Cancer Research in New ... Schools of Medicine and Dentistry have completed research which ... how some cells in the brain and nervous system ... published in the prestigious journal Cancer Cell . ... a tumour suppressor called Merlin. , The results ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 BlogHer, ... for women, this year celebrates its tenth anniversary where ... Thousands of attendees, including community leaders from the new ... representing every consumer vertical, will converge in San Jose ... conversation, and a “selfiebration” of social technology. , ...
(Date:7/22/2014)... SWAMP , the first ... has completed an upgrade that significantly improves the ... with a $23.4 million grant from the ... (DHS S&T), the Software Assurance Marketplace (SWAMP) ... to assess the security of their software, but ...
(Date:7/22/2014)... New study findings released today confirm ... patient-centered program is working to improve the coordination of ... the largest to date and includes more than 200,000 ... that focuses on delivering better quality outcomes, a better ... , “Our most recent study results clearly demonstrate the ...
Breaking Medicine News(10 mins):Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3Health News:Research brings us nearer to understanding how neuro cells turn cancerous 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 2Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 3Health News:BlogHer, Inc. Comes Home to Silicon Valley for 10th Anniversary: World’s Largest Event for Bloggers and Social Media Influencers 4Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 2Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 3Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 4Health News:The SoftWare Assurance MarketPlace (SWAMP) Gains Industry Momentum With Significantly Improved Interface Enhancements 5Health News:Horizon BCBSNJ’s 2013 Study Results Demonstrate Patient-centered Program Improves Patient Care and Lowers Costs 2Health News:Horizon BCBSNJ’s 2013 Study Results Demonstrate Patient-centered Program Improves Patient Care and Lowers Costs 3
... Global health organization PSI helps contestants spread HIV prevention ... Bahamas, Aug. 21 The Miss Universe contestants continued preparations for ... tossing water-filled condoms to test their strength and playing "Wild Fire ... The games are part of an HIV peer education workshop designed ...
... ... Mesothelioma Patients , ... Newton, MA (PRWEB) August 21, 2009 -- MesoRC.com, an online community and resource center ... diseases, provides an extra source of valuable information with the introduction of Twitter. The ...
... , , LOS ANGELES, Aug. ... the launch of Energy-X, a new lip balm that delivers an effective ... sweeteners. With zero calories, Energy-X provides the energy boost consumers want without ... "Energy-X is applied directly on the lips and is therefore ...
... , , , ... to a Benefit Concert, Dessert and Auction, featuring LA Collaboration, at ... , 1243 Artesia Blvd, Manhattan Beach, CA - (310) 372-4641 ... price of 1 tickets. , , The concert features ...
... treating a recurrent or residual brain aneurysm that was ... a multicenter study led by researchers at the University ... of 311 patients with coiled aneurysms who underwent retreatment ... death or permanent major disability was slightly over one ...
... , FRAMINGHAM, Mass. and SYDNEY, Aug. ... announced that HeartWare has surpassed 50 implants in the United States ... , , The 50th implant in the ... Houston, Texas by O.H. Frazier, MD a distinguished surgeon, scientist, and ...
Cached Medicine News:Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 2Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 3Health News:Mesothelioma Resource Center Enters Twitter World 2Health News:Energy-X Lip Balm Delivers Wake-Up Call to Consumers 2Health News:The Sensory Research Center (SRC) Offers 2 for 1 Tickets for Benefit Concert Supporting Autism, Down's Syndrome, Cerebral Palsy and Other Disabilities. 2Health News:Study finds low risk in treating previously coiled aneurysm 2Health News:Study finds low risk in treating previously coiled aneurysm 3Health News:HeartWare International Surpasses 50 Implants in the US 2Health News:HeartWare International Surpasses 50 Implants in the US 3
... The PowerEase® 500 Power ... mini-gel electrophoresis. It offers extensive ... and four custom methods for ... own preferences. The simple intuitive ...
... modified battery chargers are ... for GENIE blotters. They ... very specific voltages, giving ... laboratory power supplies. 110 ...
PS2A200 Power supply is a high current power supply ideal for all types of electrophoresis blotting and short electrophoresis runs....
Inquire...
Medicine Products: